US biotech Abcuro has reeled in $200 million in third-round financing that should allow it to complete its pivotal trial of ...

Sporadic inclusion body myositis (sIBM) presents with a characteristic ... pathways might prove helpful in arresting disease progression. sIBM is often misdiagnosed as polymyositis or other ...

The Boston-area company’s previous raises were also aimed at getting its investigational antibody treatment for inclusion ...

Funding was led by New Enterprise Associates, with participation from Foresite Capital and multiple other investors. Abcuro announced that it has obtained $200 million in Series C financing, led by ...

Myopathic (myo = muscle, pathy = disease) conditions can include polymyositis, dermatomyositis, inclusion body myositis, and various myopathies ... including the heart. The rate of progression of the ...

The funding will be used to complete the Phase II/III trial of ulviprubart, and to support commercial launch preparation.

Inclusion Body Myositis- Features asymmetric muscle weakness and distinct histopathologic findings, such as rimmed vacuoles. Drug-induced Myopathies- Commonly associated with medications like ...

New research examining the skeletal muscle cells of patients with inclusion body myositis (IBM) has revealed that the nucleic acid-binding protein TDP-43, which is normally restricted to the ...